Year: 2021

PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 1, 2021 at 8:50 a.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge,...

TULSA, Okla., Nov. 24, 2021 (GLOBE NEWSWIRE) — AAON, Inc. (NASDAQ: AAON) (“AAON” or the “Company”), a leader in innovation and production of premium quality, highly energy efficient HVAC products for nonresidential buildings, announced today that Gary Fields, CEO, and Rebecca Thompson, CFO, will participate in a virtual fireside chat at the Credit Suisse Global Industrials Conference. They will speak at 8:50 a.m. ET on Thursday, December 2, 2021. The live webcast will be accessible at https://kvgo.com/credit-suisse/aaon-dec-2021.For those interested, that same link can also be used following the live broadcast to access a replay of the webcast. About AAONAAON is engaged in the engineering, manufacturing, marketing, and sale of air conditioning and heating equipment consisting of standard, semi-custom, and custom rooftop units,...

VANCOUVER, British Columbia, Nov. 24, 2021 (GLOBE NEWSWIRE) — Surge Copper Corp. (TSXV: SURG) (OTCQX: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) is pleased to announce complete assay results for hole S21-268 from the Company’s 100% owned Ootsa Property in British Columbia, and an update on the Company’s ongoing resource update for the Ootsa Property. The Company previously released the results for the top portion of hole S21-268 (see October 12, 2021 Press Release). HighlightsHole S21-268 intersected 422 metres grading 0.52% copper equivalent from 20 metres downhole depth, including 200 metres grading 0.60% copper equivalent This includes a zone of higher grade mineralization returning 0.69% copper equivalent over 76 metres from 324 metres depthComplete assay results have been received for hole S21-268 with significant...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Nov. 24, 2021 (GLOBE NEWSWIRE) — Burin Gold Corp. (“Burin Gold” or the “Company”) is pleased to announce that its common shares will commence trading on the TSX Venture Exchange (“TSX-V”) today at market open under the symbol “BURG”. This follows the closing of the Company’s successful initial public offering (“IPO”) led by Haywood Securities Inc. and Laurentian Bank Securities Inc. and including Echelon Wealth Partners Inc. David Clark, CEO of the Company, said: “On behalf of Burin Gold, I would like to thank our existing and new shareholders for their support throughout this successful IPO process. We are looking forward to starting this next pivotal chapter of Burin Gold’s growth as a listed company and owe...

SANTA FE, N.M. and MALVERN, Pa., Nov. 24, 2021 (GLOBE NEWSWIRE) — Avisa Diagnostics Inc. (CSE:AVBT) (“Avisa” or the “Company”), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, reports that, due to current liquidity limitations, the Company does not anticipate that it will be able to file its unaudited financial statements for the period ended September 30, 2021, related management discussion and analysis and applicable CEO and CFO certifications (collectively the “Interim Filings”) by the filing deadline of November 29, 2021. The Company is presently unable to confirm when the Interim Filings will be filed. The Company confirms that, other than as disclosed by the Company prior to the date hereof, there...

A total of 7,466 hotels or 722,983 hotel rooms in operation as of September 30, 2021. Hotel turnover1 increased 15.4% year-over-year to RMB12.2 billion for the third quarter of 2021. Excluding Steigenberger Hotels AG and its subsidiaries (“DH”, or “Legacy-DH”), hotel turnover increased 14.0% year-over-year for the third quarter of 2021. Revenue increased 11.6% year-over-year to RMB3.5 billion (US$547 million)2 for the third quarter of 2021, in line with revenue guidance previously announced of 8% to 12% compared to the third quarter of 2020. Revenue from Legacy-Huazhu3 for the third quarter of 2021 increased 7.4% year-over-year, in line with revenue guidance previously announced of 4% to 8%. Net loss attributable to Huazhu Group Limited was RMB137 million (US$22 million) for the third quarter of 2021, compared with net loss attributable...

Management to host webcast and conference call today at 8:30 a.m. ET SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold. The partial clinical hold was initiated following the Company’s recent report to the FDA of a Grade 5 serious adverse event (patient death) potentially associated with differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML. Patients currently enrolled in the Phase 1b study may continue to receive...

GUANGZHOU, China, Nov. 24, 2021 (GLOBE NEWSWIRE) — Fanhua Inc. (“Fanhua” or “the Company”) (Nasdaq: FANH), a leading independent financial services provider in China, today announced that it has partnered with Aviva-COFCO Life Insurance Co., Ltd (“Aviva-COFCO”) to launch “Huaying Guardian No.1”, an innovative, customized critical illness (“CI”) plan. Huaying Guardian No.1 offers twofold protection with both a lump sum payout of critical illness benefits and coverage for CI-related medical treatment. In addition, during the payment period, the insured amount will increase by 5% per annum, effectively guarding against inflation risk. The plan is reported to be first of its kind in China’s life insurance industry. Mr. Chunlin Wang, chairman and chief executive officer of Fanhua, stated, “As a leading insurance intermediary company...